TEE
CRBP icon

Tibra Equities Europe’s Corbus Pharmaceuticals CRBP Stock Holding History

Tibra Equities Europe’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,850
Closed -$266K – 78
2021
Q2 		$266K Buy
+4,850
New +$269K 0.08% 200

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Tibra Equities Europe's CRBP Position: Q3 2021 in Review

Tibra Equities Europe sold out of Corbus Pharmaceuticals (CRBP) in Q3 2021, closing a stake of 4,850 shares — an estimated $266K sold.

Tibra Equities Europe first reported a position in CRBP in Q2 2021 and held it in 1 quarter. The position peaked at $266K in Q2 2021. 85 funds tracked by Wall St. Rank hold CRBP as of Q3 2021.

  • Tibra Equities Europe reported no remaining Corbus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 4,850 Corbus Pharmaceuticals shares in Q3 2021, an estimated $266K.
  • Tibra Equities Europe first reported a position in Corbus Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Corbus Pharmaceuticals position peaked at $266K in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.